| |
| Bringing a new therapeutic to market is a complex, time-consuming journey, but the right CDMO partnership can change everything. That’s why Outsourced Pharma serves to connect you with ideal collaborators to accelerate your project needs. To help you achieve your goals, we’re excited to announce that the Outsourced Pharma Capacity Update (OPCU) has evolved into the Outsourced Pharma Capabilities Update — a refreshed name that better reflects the value we deliver. While capacity insights remain core to our mission, this rebrand highlights our expanded focus on capabilities, expertise, and innovation across the CDMO landscape. Looking ahead, our PARTNER WEEK continues to grow, with plans for an extended program and sessions organized by capability area throughout 2026. This structure will make it easier than ever to identify the right partner, no matter where you are in the development or manufacturing process. Join us for the next Outsourced Pharma Capabilities Update on January 27, 2026, and discover the partners, insights, and expertise that can bring your therapeutic vision to life. Fill Finish Capabilities Update | January 27. 2026 at 11:00 AM EST
Viral Vectors Capabilities Update | January 27, 2026 at 1:00 PM EST |
|
| Ascend & ABL Inc. | We provide end-to-end services to commercial, academic, and government clients, spanning process innovation through development, GMP manufacturing, QC testing, to aseptic fill/finish. | Request Information | Ascend & ABL Inc. |
|
| Vector BioMed | Founded on lentiviral vector design and manufacturing excellence, VBM and the LENTIVERSE™ technology platform provide a full suite of tools to deliver therapies and develop next-gen products. | Request Information | Vector BioMed |
|
| Andelyn Biosciences | Here, we present a risk-based framework for identity testing of ancillary raw materials, with emphasis on implementation based on product contact, classification, and manufacturing stage. | Request Information | Andelyn Biosciences |
|
| | SGS | We provide a range of solutions, including method development, validation, and transfer; PK and PD bioanalysis; ELISA and multiplex assays; bioassays; and immunogenicity testing. | Request Information | SGS |
|
| KBI Biopharma | Leveraging decades of expertise, analytical capabilities, and regulatory knowledge, we deliver phase-appropriate solutions that streamline development, reduce risk, and accelerate timelines. | Request Information | KBI Biopharma |
|
| Mabion | This end-to-end solution covers every development stage, from early clone selection and small-scale manufacturing to process scale-up, large-scale production, and quality control. | Request Information | Mabion |
|
| Alcami | Whether you're preparing for IND, scaling commercial operations, or navigating complex regulatory pathways, gain actionable strategies and updates to help you move forward with confidence. | Request Information | Alcami |
|
| |
|
|
